SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

Lomedeucitinib

Cat. No.: HY-160144S

CAS No.: 2328068-29-5

Molecular Formula: $C_{18}H_{17}D_3N_6O_4S$

Molecular Weight: 419.47

Target: Isotope-Labeled Compounds; JAK; IFNAR

Pathway: Others; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt; Immunology/Inflammation

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (238.40 mM; Need ultrasonic)

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	2.3840 mL	11.9198 mL	23.8396 mL
5 mM	0.4768 mL	2.3840 mL	4.7679 mL
10 mM	0.2384 mL	1.1920 mL	2.3840 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Lomedeucitinib (BMS-986322) is a tyrosine protein kinase (TYK2) inhibitor. Lomedeucitinib has anti-inflammatory activity and significant inhibitory effect on IFNα (IC_{50}=0.047 μM) production downstream of IL-12/TYK2. Lomedeucitinib is indicated for the study of plaque psoriasis and pruritus[1][2][3].

IC_{50} & Target

IC50⊠0.047 μM (IFNα)[2]

REFERENCES

[1]. Drakos A, et al. Emerging Oral Therapies for the Treatment of Psoriasis: A Review of Pipeline Agents[J]. Pharmaceutics, 2024, 16(1): 111.

[2]. Zhang K, et al. Development and therapeutic implications of tyrosine kinase 2 inhibitors[J]. Journal of Medicinal Chemistry, 2023, 66(7): 4378-4416.

[3]. Andrew Nicholas Billin, et al. Il-31 modulators for treating fxr-induced pruritis. WO2022266444A1. 2022-06-17

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA